This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

March 19, 2026

To whom it may concern:

Company	D. Western Therapeutics Institute, Inc.
Representative	Yuichi Hidaka, President and CEO
	(Securities code: 4576; TSE Growth)
Contact	Sayako Matsubara, Director
TEL	052-218-8785

Announcement regarding completion of the observation period for all subjects in the global phase III clinical study of “K-321,” a treatment for Fuchs endothelial corneal dystrophy

With respect to K-321, an ophthalmic solution whose active ingredient is the Rho kinase (Note) inhibitor ripasudil hydrochloride hydrate that we discovered, we hereby announce that we have received a notice from Kowa Company, Ltd., our licensee (hereinafter “Kowa”), that the observation period for subjects has been completed in the remaining study of the two global phase III clinical studies (hereinafter the “Study”). This remaining study was previously announced on June 20, 2025.
Accordingly, together with the announcement dated November 21, 2025, entitled ‘Announcement regarding completion of the observation period for subjects in the global phase III clinical study of “K-321,” a treatment for Fuchs endothelial corneal dystrophy’ the observation periods for all global Phase III clinical studies have now been completed.

The Study is being conducted in multiple countries and regions, including the United States and Europe, targeting patients with Fuchs endothelial corneal dystrophy. It aims to evaluate the efficacy and safety of the product administered as an eye drop after Descemet’s membrane stripping surgery in comparison with a placebo.
Going forward, data from the subjects will be collected and analyzed statistically. We will promptly announce the results once they are available.
We expect to file for approval with the FDA in 2027.

Fuchs endothelial corneal dystrophy causes damage to the corneal endothelium as the disease progresses. The development of effective therapeutic agents is eagerly awaited, as corneal transplantation is currently the main option for corneal endothelial damage with severe visual impairment. We and Kowa will continue to develop“K-321”to provide patients with new treatment options.

Due to this matter, there will be no change to the earnings forecast for the fiscal year ending December 2026.

Ripasudil hydrochloride hydrate

Kowa began marketing GLANATEC® Ophthalmic Solution 0.4%, which contains ripasudil hydrochloride hydrate as the active ingredient, in Japan in December 2014. As a Rho kinase inhibitor, ripasudil hydrochloride hydrate has shown potential to act on kinases in the eye, with the possibility that indications could be expanded to include other ophthalmic diseases. Kowa is undertaking the clinical study on K-321 with a view to obtaining approval for the indication of Fuchs endothelial corneal dystrophy.

end

Explanation of terms

(Note) Rho kinase (ROCK: Rho-associated, coiled-coil containing protein kinase)
Rho kinase is one of the protein phosphorylation enzymes (protein kinase). This enzyme is involved in the regulation mechanism of versatile cell responses based on the Rho-ROCK information transmission.